发明名称 |
VERFAHREN ZUR BEHANDLUNG VON GEFITINIB- RESISTENTEM KREBS |
摘要 |
<p>The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.</p> |
申请公布号 |
AT504299(T) |
申请公布日期 |
2011.04.15 |
申请号 |
AT20060720163T |
申请日期 |
2006.02.02 |
申请人 |
THE GENERAL HOSPITAL CORPORATION;WYETH LLC |
发明人 |
HABER, DANIEL;BELL, DAPHNE WINIFRED;SETTLEMAN, JEFFREY E.;SORDELLA, RAFFAELLA;GODIN-HEYMANN, NADIA G.;KWAK, EUNICE L.;RABINDRAN, SRIDHAR KRISHNA |
分类号 |
A61K31/4706;A61K38/17;A61P35/00 |
主分类号 |
A61K31/4706 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|